Parthenon LLC Trims Position in Stryker Co. (NYSE:SYK)

Parthenon LLC trimmed its stake in Stryker Co. (NYSE:SYK) by 1.6% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 38,380 shares of the medical technology company’s stock after selling 610 shares during the period. Stryker makes up about 1.7% of Parthenon LLC’s investment portfolio, making the stock its 18th biggest position. Parthenon LLC’s holdings in Stryker were worth $13,819,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dunhill Financial LLC boosted its holdings in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Darwin Wealth Management LLC bought a new stake in Stryker during the 3rd quarter valued at $36,000. Activest Wealth Management purchased a new stake in shares of Stryker in the 4th quarter worth $36,000. Crews Bank & Trust bought a new position in shares of Stryker during the 4th quarter worth $39,000. Finally, Hara Capital LLC purchased a new position in shares of Stryker during the third quarter valued at $42,000. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Stifel Nicolaus increased their price objective on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Finally, The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $420.68.

Stryker Trading Up 0.7 %

NYSE SYK opened at $388.30 on Thursday. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a fifty day simple moving average of $377.69 and a two-hundred day simple moving average of $368.08. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $148.17 billion, a P/E ratio of 50.04, a P/E/G ratio of 2.90 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business posted $3.46 earnings per share. On average, analysts forecast that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.